FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2157784057> ?p ?o ?g. }

• W2157784057 endingPage "826" @default.
• W2157784057 startingPage "821" @default.
• W2157784057 abstract "To compare mitomycin C plus vindesine plus etoposide (MEV) vs. mitomycin C plus vindesine plus cisplatin (MVP) in the treatment of stage IV non-small-cell lung cancer.204 patients were entered in a phase III multicentre randomised trial from June 1990 to December 1994 and stratified according to the ECOG performance status (0-1 vs. 2). MVP was given in the following dosages: mitomycin C 8 mg/m2+vindesine 3 mg/m2+cisplatin 100 mg/m2 i.v. day 1 and vindesine 3 mg/m2 i.v. day 8 with cycles repeated every 4 weeks. MEV was given in the following dosages: mitomycin C 8 mg/m2+vindesine 3 mg/ m2 i.v. day 1 and etoposide 100 mg/m2 i.v. days 1 to 3 with cycles repeated every 3 weeks. For both treatments a maximum of 6 cycles was planned. Response and toxicity were evaluated according to WHO. Subjective responses were assessed by numerical scales. Analyses were made on the basis of intent to treat.The objective response rate was 21.4% (1 CR + 21 PR among 103 patients) in the MEV and 28.7% (1 CR + 28 PR among 101 patients) in the MVP arm (P = 0.48). Symptoms were similar in the two arms. 196 patients progressed and 182 died. The median times to progression were 10 weeks (95% CI 9-12) and 12 weeks (95% CI 10-15) and median survivals were 29 weeks (95% CI 25-36) and 28 weeks (95% CI 25-35) in the MEV and MVP arms, respectively. The relative risks of progressing and of dying were 0.89 (95% CL 0.66-1.20) and 0.96 (95% CL 0.71-1.30), respectively, for patients receiving MVP as compared with those receiving MEV at multivariate analysis adjusted by sex, age, histologic type, number of metastatic sites, performance status at entry, and centre.In the present study, no significant differences were observed in response rate, survival or palliation of symptoms between the MEV and MVP regimens, while toxicity was significantly more frequent and severe with MVP. Thus, MEV should be considered a reasonable alternative to the MVP regimen in the treatment of stage IV NSCLC." @default.
• W2157784057 created "2016-06-24" @default.
• W2157784057 creator A5000803284 @default.
• W2157784057 creator A5001240893 @default.
• W2157784057 creator A5001495249 @default.
• W2157784057 creator A5011707388 @default.
• W2157784057 creator A5013748999 @default.
• W2157784057 creator A5015740152 @default.
• W2157784057 creator A5016655393 @default.
• W2157784057 creator A5017866134 @default.
• W2157784057 creator A5022553664 @default.
• W2157784057 creator A5032078755 @default.
• W2157784057 creator A5044926112 @default.
• W2157784057 creator A5045384053 @default.
• W2157784057 creator A5054449862 @default.
• W2157784057 creator A5066081183 @default.
• W2157784057 creator A5071099107 @default.
• W2157784057 creator A5078561497 @default.
• W2157784057 creator A5078562748 @default.
• W2157784057 creator A5080823945 @default.
• W2157784057 creator A5086894884 @default.
• W2157784057 date "1996-10-01" @default.
• W2157784057 modified "2023-10-18" @default.
• W2157784057 title "Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial" @default.
• W2157784057 cites W2034519241 @default.
• W2157784057 cites W2039327157 @default.
• W2157784057 cites W2066465011 @default.
• W2157784057 cites W2071796418 @default.
• W2157784057 cites W2129793485 @default.
• W2157784057 cites W2150379801 @default.
• W2157784057 cites W2167805334 @default.
• W2157784057 cites W2229315518 @default.
• W2157784057 cites W2242204182 @default.
• W2157784057 cites W2262590927 @default.
• W2157784057 cites W4239714259 @default.
• W2157784057 cites W4293241248 @default.
• W2157784057 doi "https://doi.org/10.1093/oxfordjournals.annonc.a010761" @default.
• W2157784057 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8922196" @default.
• W2157784057 hasPublicationYear "1996" @default.
• W2157784057 type Work @default.
• W2157784057 sameAs 2157784057 @default.
• W2157784057 citedByCount "32" @default.
• W2157784057 countsByYear W21577840572015 @default.
• W2157784057 countsByYear W21577840572016 @default.
• W2157784057 countsByYear W21577840572017 @default.
• W2157784057 countsByYear W21577840572019 @default.
• W2157784057 countsByYear W21577840572023 @default.
• W2157784057 crossrefType "journal-article" @default.
• W2157784057 hasAuthorship W2157784057A5000803284 @default.
• W2157784057 hasAuthorship W2157784057A5001240893 @default.
• W2157784057 hasAuthorship W2157784057A5001495249 @default.
• W2157784057 hasAuthorship W2157784057A5011707388 @default.
• W2157784057 hasAuthorship W2157784057A5013748999 @default.
• W2157784057 hasAuthorship W2157784057A5015740152 @default.
• W2157784057 hasAuthorship W2157784057A5016655393 @default.
• W2157784057 hasAuthorship W2157784057A5017866134 @default.
• W2157784057 hasAuthorship W2157784057A5022553664 @default.
• W2157784057 hasAuthorship W2157784057A5032078755 @default.
• W2157784057 hasAuthorship W2157784057A5044926112 @default.
• W2157784057 hasAuthorship W2157784057A5045384053 @default.
• W2157784057 hasAuthorship W2157784057A5054449862 @default.
• W2157784057 hasAuthorship W2157784057A5066081183 @default.
• W2157784057 hasAuthorship W2157784057A5071099107 @default.
• W2157784057 hasAuthorship W2157784057A5078561497 @default.
• W2157784057 hasAuthorship W2157784057A5078562748 @default.
• W2157784057 hasAuthorship W2157784057A5080823945 @default.
• W2157784057 hasAuthorship W2157784057A5086894884 @default.
• W2157784057 hasBestOaLocation W21577840571 @default.
• W2157784057 hasConcept C126322002 @default.
• W2157784057 hasConcept C141071460 @default.
• W2157784057 hasConcept C162156334 @default.
• W2157784057 hasConcept C2776256026 @default.
• W2157784057 hasConcept C2776694085 @default.
• W2157784057 hasConcept C2776755627 @default.
• W2157784057 hasConcept C2778119113 @default.
• W2157784057 hasConcept C2779321808 @default.
• W2157784057 hasConcept C2779338040 @default.
• W2157784057 hasConcept C2779429289 @default.
• W2157784057 hasConcept C71924100 @default.
• W2157784057 hasConcept C90924648 @default.
• W2157784057 hasConceptScore W2157784057C126322002 @default.
• W2157784057 hasConceptScore W2157784057C141071460 @default.
• W2157784057 hasConceptScore W2157784057C162156334 @default.
• W2157784057 hasConceptScore W2157784057C2776256026 @default.
• W2157784057 hasConceptScore W2157784057C2776694085 @default.
• W2157784057 hasConceptScore W2157784057C2776755627 @default.
• W2157784057 hasConceptScore W2157784057C2778119113 @default.
• W2157784057 hasConceptScore W2157784057C2779321808 @default.
• W2157784057 hasConceptScore W2157784057C2779338040 @default.
• W2157784057 hasConceptScore W2157784057C2779429289 @default.
• W2157784057 hasConceptScore W2157784057C71924100 @default.
• W2157784057 hasConceptScore W2157784057C90924648 @default.
• W2157784057 hasIssue "8" @default.
• W2157784057 hasLocation W21577840571 @default.
• W2157784057 hasLocation W21577840572 @default.
• W2157784057 hasOpenAccess W2157784057 @default.
• W2157784057 hasPrimaryLocation W21577840571 @default.
• W2157784057 hasRelatedWork W2034519241 @default.

• next